This Humanized Monoclonal antibody specifically detects ErbB2/Her2 (Trastuzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.
Catalog No. ABIN7795082
Quick Overview for Recombinant ErbB2/Her2 (Trastuzumab Biosimilar) antibody (ABIN7795082)
Target
ErbB2/Her2 (Trastuzumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Conjugate
This ErbB2/Her2 (Trastuzumab Biosimilar) antibody is un-conjugated
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Grade
Research Grade
Clone
4D5-8
Expression System
Mammalian cells
Purpose
Trastuzumab Biosimilar, Endotoxin 0.05 EU/mg
Characteristics
Trastuzumab, a humanized monoclonal antibody, interferes with the HER2/neu receptor and is mainly used to treat certain breast cancers, especially HER2-positive metastatic breast cancer. Combined with chemotherapy, trastuzumab increases both survival and response rate. There are four closely related receptor tyrosine kinases in the ErbB family of receptors: EGFR (ErbB-1, HER1 in humans), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Bound by members of the epidermal growth factor family (EGF-family) of extracellular protein ligands, the HER receptors embedded in the cell membrane promote cell growth and division by turning genes on and off. The HER2 pathway stimulates cell proliferation if it normally functions, when HER2 is overexpressed, cell growth accelerates beyond its normal limits, which happens in some cancers, notably certain types of breast cancer.
Purification
Protein A or G affinity column
Purity
>95 % by reducing SDS-PAGE
Endotoxin Level
Less than 0.5 EU/mg of protein as determined by LAL method